Duke Comp Cancer Inst. Core Support Grant

杜克大学癌症研究所

• 批准号: 8322901
• 负责人: ANTHONY MEANS
• 金额: $ 7.5万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8322901
• 关键词: American Cancer Society; Basic Science; Biomedical Research; Cancer Biology; Cancer Patient; Charge; Clinical Oncology; Collaborations; Data; Department of Defense; Development; Developmental Biology; Enrollment; Funding; Future; Genomics; Goals; Grant; Institutes; Interdisciplinary Study; Journals; Laboratories; Malignant Neoplasms; National Cancer Institute; Paper; Patients; Peer Review; Pilot Projects; PubMed; Publications; Publishing; Request for Applications; Research; Research Institute; Resource Sharing; Resources; Scientific Advances and Accomplishments; Signal Pathway; Societies; Source; Testing; Therapeutic Clinical Trial; anticancer research; cancer risk; chemotherapy; improved; innovation; insight; member; oncology; operation; programs; statistical center

The recently reorganized Duke Comprehensive Cancer Institute (DCCI) is charged to serve as the center of all Duke activities in cancer, with an imperative to oversee all of the Duke cancer operations in the future. As a matrix center in one of the largest biomedical research institutes, the DCCI has been continuously supported by the National Cancer Institute (NCI) for over 36 years, by leveraging Duke's basic research strengths with significant clinical oncology research excellence which is enabled by treating 5,581 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. Total membership in the DCCI is 285 members, with members having an increasingly prominent focus in cancer research and increased amount of NCI funding since 2004. Total funding for program members is $331,617,013, of which $269,525,804 is from peer-reviewed sources. A cancer focus is illustrated by $77,785,582 or 23.5% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004-2008, program members published 6,941 papers in peer-reviewed journals cited in PubMed. Of these publications, 10% are the result of intra-programmatic collaborations and 19% due to inter-programmatic collaborations. In this competitive renewal application, we request support our membership in 11 Research Programs supported by 17 Shared Resources. DCCI members made significant scientific advances including: the development of innovative genomic tests to predict which cancer patients would respond to specific chemotherapy, and basic insight into critical signaling pathways in cancer and developmental biology. The DCCI oversees all cancer related philanthropy at Duke, and these funds have been used to support recruitment of new members, innovative pilot projects, support of multidisciplinary research, and new laboratory and administrative space. This application for ongoing support of the DCC articulates the principles, goals and strategies for propelling the DCCI to fully leverage the enormous advances in biomedical research at Duke and beyond, to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.

最近重组的杜克大学综合癌症研究所（DCCI）被控作为中心 杜克大学的所有活动都必须在将来监督所有杜克癌症业务。作为 DCCI一直是最大的生物医学研究机构之一的基质中心 由国家癌症研究所（NCI）支持了36多年，通过利用杜克的基础研究 具有重要临床肿瘤研究卓越的优势，可以通过治疗5,581个新的 每年癌症患者，每年将1,000多名患者纳入治疗临床试验，并增强 根据国家肿瘤研究资源的存在，例如两个数据和统计中心 NCI资助的合作团体。 DCCI的总会员人数为285名，成员有一个 自2004年以来，在癌症研究和NCI资金中增加的重点越来越突出。 计划成员的资金为331,617,013美元，其中269,525,804美元来自同行评审的资料。一个 癌症的焦点由NCI，美国癌症协会或 国防部。从2004年至2008年，计划成员在同行评审中发表了6,941篇论文 在PubMed引用的期刊。在这些出版物中，有10％是概括性内合作的结果 19％由于程序间合作。在此竞争性更新申请中，我们请求支持 我们在11个研究计划中的成员资格，得到了17个共享资源的支持。 DCCI成员制作 重大科学进步，包括：创新基因组检验的发展以预测哪些癌症 患者将对特定的化学疗法做出反应，以及对癌症关键信号通路的基本见解 和发育生物学。 DCCI监督杜克大学的所有与癌症有关的慈善事业，这些资金 已被用来支持新成员的招聘，创新的试点项目，多学科的支持 研究以及新的实验室和行政空间。此申请持续支持 DCC阐明了推动DCCI充分利用DCCI的原则，目标和策略 杜克大学及其他地区生物医学研究的巨大进步，以改善和延长癌症的生活 患有癌症的患者，有癌症的风险，并将这些患者交付给社会。